Objectives. Pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) has a poor prognosis compared to PAH associated with other connective tissue diseases (CTD). The objective of this study was to examine the difference in hemodynamic state between SSc-PAH and other CTD-PAH by performing cardiac magnetic resonance (CMR) imaging.
Introduction
Pulmonary arterial hypertension (PAH) is of clinical significance in connective tissue diseases (CTD) because of its high mortality. In particular, several studies have demonstrated poor prognosis of patients with PAH associated with systemic sclerosis (SSc) compared to those with PAH associated with other CTD (1-3) or idiopathic PAH (4) (5) (6) (7) . Furthermore, PAH is a relatively common complication of SSc, occurring in about 10 to 12% of the patients (8) (9) (10) . Early detection as well as accurate evaluation of the severity of PAH is therefore critical in order to improve the prognosis of patients with SSc.
Cardiac magnetic resonance (CMR) imaging has recently been performed in PAH patients. CMR is useful in the estimation of right heart catheterization (RHC) measurements, such as mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) and therefore represents a non-invasive diagnostic tool of PAH (11) (12) (13) . In addition, CMR has been shown to sensitively detect clinical and subclinical cardiac involvement. At least one cardiac abnormality, such as reduced ejection fraction and diastolic dysfunction, was observed at CMR in up to 75% of patients with SSc (14) .
Here we hypothesized that CMR may detect some difference in the hemodynamic state between SSc-PAH and other CTD-PAH to differentiate prognosis in SSc patients.
Materials and methods

Study design
The present retrospective, observational clinical study was conducted in a single center to assess the value of CMR imaging in patients with CTD-PAH. We enrolled 40 consecutive CTD patients who had undergone RHC and CMR within one week from January 2010 to October 2015. All patients had been suspected of having PAH with either unexplainable dyspnea or increased tricuspid regurgitation velocity (>2.8 m/s) measured with echocardiography. CTD-PAH patients were defined as those who had any CTD and met the criteria of pre-capillary pulmonary hypertension (PH) [mPAP of 25 or more mmHg and pulmonary arterial wedge pressure (PAWP) of 15 (20) , the 2012 ACR classification criteria for Sjögren's syndrome (21) , the classification criteria for definite antiphospholipid syndrome (22) , and 2010 ACR/EULAR classification criteria for rheumatoid arthritis (23), respectively. All non-SSc patients did not meet any criteria of SSc (1980 ACR SSc criteria (24), LeRoy/Medsger SSc criteria (25), nor 2013 ACR/EULAR SSc criteria (16)). The study protocol was approved by the ethics committee of the Hokkaido University
Hospital. The present study complied with the Declaration of Helsinki.
Cardiac Magnetic Resonance Imaging
CMR was performed using a 1.5-Tesla Philips Achieva magnetic resonance imaging system (Philips Medical Systems, Best, The Netherlands) with a cardiac five-channel coil, equipped with Master gradients (maximum gradient amplitude, 33 mT/m; maximum slew rate, 100 mT/m/m). Imaging was performed with breath-holding in expiration, using a vector-cardiographic method for electrocardiogram gating. Images were evaluated using commercially available software (Extended MR Work Space: ver. Gd-DTPA (0.1mmol/kg, Magnevist; Berlex Laboratories, Wayne, NJ) was intravenously administered.
Ten minutes after the injection, a breath-holding, inversion recovery-prepared, three dimensional turbo field echo pulse sequence with electrocardiogram gating was performed to obtain a delayed enhancement image with fat saturation of spectral presaturation with inversion recovery.
Statistical analysis
Categorical variables are expressed as percentages, and continuous variables are expressed as mean ± standard deviation (SD) for those normally distributed or otherwise as medians and interquartile ranges (IQR). P-values less than 0.05 were considered significant. Correlation coefficients were assessed by Spearman rank method. Analysis of covariance (ANCOVA) was used to compare two regression slopes.
Kaplan-Meier survival estimates were stratified by the optimal cut-off values and compared by log-rank tests. All statistical analyses were carried out with IBM SPSS Statistics (version 22.0.0, Inc.).
Results
Patients' characteristics
A total of 40 CTD patients were enrolled in this study (Table 1) . Of 40 patients, 32 (80%) met the criteria of pre-capillary PH, 2 (5%) had isolated post-capillary PH, and 6 (15%) did not have PH. Thirty-seven (93%) were female. Mean age on the enrollment was 53.8 ± 14.5 years. WHO functional class on the enrollment was I, II, III and IV in 1 (3%), 14 (35%), 22 (55%) and 3 (8%) patients, respectively.
Twenty-one (53%) patients had SSc, 8 (20%) had systemic lupus erythematosus, 5 (13%) had mixed connective tissue disease, and 6 (15%) had other CTD including polymyositis, primary Sjögren's syndrome, primary antiphospholipid syndrome and rheumatoid arthritis.
RHC and CMR measurements at baseline
All patients enrolled in this study underwent RHC and CMR at the same period. Systolic, diastolic and (Table 1) .
Difference in RHC and CMR measurements between SSc and non-SSc patients
To evaluate the difference in hemodynamic state between SSc and non-SSc patients with pre-capillary PH, we next compared RHC and CMR measurements in the two groups ( Table 2 ). In SSc patients, mPAP was lower than in non-SSc patients. Conversely, WHO functional class, PVR and CMR measurements were not different in the two groups. These results indicate that RHC measurements alone may not reflect the severity of PAH in SSc patients, presumably due to the presence of clinical or subclinical cardiac dysfunction in that population.
Correlation between mPAP and CMR measurements
To detect SSc-related cardiac dysfunction, we analyzed the correlation between mPAP and CMR measurements in either SSc or non-SSc patients. Among 9 parameters measured at CMR (Table 2) Figure 1D ). Conversely, in the scattergrams of mPAP-RVESV/LVESV or mPAP-RVEF/LVEF correlation, approximate lines were similar in the two groups ( Figure 1E, 1F ).
Among the 9 CMR parameters, although not statistically significant, the difference between two slopes, SSc and non-SSc, was the largest in RVEDV/LVEDV (Table 3) . To confirm the difference in mPAP-RVEDV/LVEDV correlation between SSc and non-SSc patients, we also evaluated the ratio of RVEDV/LVEDV to mPAP. In SSc patients, (RVEDV/LVEDV)/mPAP was significantly higher compared to non-SSc patients (Table 2 ). Although duration from PH onset to study entry was shorter and treatment with vasodilators was less frequent in SSc than non-SSc patients (Table 2 ), no significant relationship was observed between these factors and (RVEDV/LVEDV)/mPAP (data not shown). These results indicate that RVEDV/LVEDV reflects not only the severity of PAH but also SSc-related cardiac dysfunction.
Follow-up study
Of 32 patients with pre-capillary PH enrolled in this study, 17 patients underwent follow-up CMR as well as follow-up RHC synchronously. All patients were treated with at least one vasodilator during follow-up.
In most of the patients, mPAP, PVR and RVEDV/LVEDV were decreased following treatment ( Figure   2A , 2B, 2C), again suggesting RVEDV/LVEDV as an indicator of PAH severity. RVEDV/LVEDV was increased in 3 patients ( Figure 2F ) while mPAP and PVR were decreased in 2 of the 3 patients ( Figure 2D ,
Discussion
We here demonstrate the altered bi-ventricular interplay detected at CMR as SSc-related cardiac involvement which reflects poor prognosis of SSc-PAH. To date, several studies have indicated the poor prognosis of patients with SSc-PAH compared to those with other CTD associated or idiopathic PAH, however the reason for this remains to be elucidated (1, 4, 5) . In those studies, mPAP and PVR were similar or even lower in SSc-PAH patients compared to other PAH patients (4) . Consistent with these data, mPAP was lower and PVR was similar in SSc patients compared to non-SSc patients in our study. It is therefore suggested that RHC measurements do not always predict the prognosis of patients with SSc-PAH correctly.
CMR has been shown to estimate RHC measurements as well as to provide functional and morphological cardiac information. A recent study performed by Swift AJ, et al. (11) indicated that mPAP could be accurately estimated using ventricular mass index, defined as RV mass divided by LV mass, and intraventricular septal angle, both of which represent the interplay between right and left ventricle. They also showed that these two parameters, compared to other LV or RV indexes, better correlated with mPAP. Consistent with these data, RVEDV/LVEDV, RVESV/LVESV and RVEF/LVEF, which also represent bi-ventricular interplay, correlated well with mPAP in our study.
Conversely, a novel aspect of this study was the examination of differences between RHC and CMR measurements. RVEDV/LVEDV and mPAP were differently correlated in SSc and non-SSc patients. In SSc patients, the ratio of RVEDV/LVEDV to mPAP was significantly higher compared to non-SSc patients. Furthermore, in our follow-up study, RVEDV/LVEDV was increased with high mortality in 2 SSc patients with decreased mPAP and PVR whose PAH were conventionally considered ameliorated.
These results indicate that the changes of RHC and CMR measurements following treatment or over time may not always be synchronized. In contrast to other PAH patients, SSc-PAH patients may develop "primary" cardiac involvement due to fibrotic, inflammatory or ischemic myocardial damage as well as "secondary" cardiac dysfunction due to elevated pulmonary arterial pressure (8) . Cardiac involvement has been found to be more common than previously expected in SSc patients (27). CMR detected clinical or subclinical cardiac involvement, such as LV diastolic dysfunction and myocardial delayed contrast enhancement, in up to 75% of patients with SSc (14) . Taken together, CMR can detect "primary" cardiac involvement of SSc which is difficult to evaluate with RHC and may be an indicator of a poor prognosis in SSc-PAH patients.
Myocardial remodeling has been shown to occur in PAH patients (28). RV adapts to the increased afterload by thickening its wall. In SSc-PAH patients, however, RV mass was less increased compared to idiopathic PAH patients, indicating an impaired cardiac adaptation in SSc-PAH (29). Another study performed by Tedford RJ, et al. indicated an impairment of RV contractility, evaluated with RV pressure-volume relations, to compensate for the high afterload in SSc-PAH patients (30). Furthermore, they recently demonstrated the depressed contractile reserve of RV and consequent exercise-associated
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RV dilation in SSc-PAH patients (31). In our follow-up study, 2 SSc patients exhibited deteriorated RVEDV/LVEDV in spite of ameliorated mPAP and PVR following treatment. These patients were not likely to compensate even for the decreased afterload following treatment because of the deterioration of "primary" cardiac involvement (Figure 4 ).
LV kinetic abnormalities such as LV reduced ejection fraction and diastolic dysfunction, compared to RV kinetic abnormalities, have been shown to be 3 times more frequently detected with CMR in SSc patients (14) . In our study, LVEDVI and LVEDVI/mPAP were higher in SSc patients than in non-SSc patients, but the differences were not statistically significant. Conversely, RVEDVI/mPAP was higher with statistical significance in SSc patients than in non-SSc patients. These results suggest that SSc patients do not only have left heart disease frequently, but they also easily develop right heart dilation, which may be due to impaired compensation for afterload, if PAH is complicated.
We also evaluated myocardial abnormalities with CMR. Although not statistically significant, myocardial delayed contrast enhancement was frequently found in SSc patients (80%) compared to non-SSc patients (59%) ( Table 2 ). Myocardial abnormalities have been shown to be observed not only in patients with SSc but also in those with idiopathic or CTD associated PAH (32, 33). Further studies are needed to evaluate whether these changes are useful to detect "primary" cardiac involvement of patients with SSc-PAH.
The limitations of our study are the small sample size, single center design, and retrospective observations.
Due to the limited sample size, we included all patients who met the criteria of pre-capillary PH but did 14 not exclude patients who had lung diseases concomitantly. The impact of pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis on CMR parameters was not evaluated due to the lack of histopathological assessment. In the comparison of mPAP-RVEDV/LVEDV correlation between SSc and non-SSc patients, we could obtain statistical significance only with unpaired t-test by comparing the ratio of RVEDV/LVEDV to mPAP but not with ANCOVA by comparing two regression slopes.
Although CTD-PAH is a rare disease and CMR is not widely performed, prospective multi center studies in a large sample may confirm our findings.
In summary, our data provides the first evidence of SSc-related bi-ventricular interplay and its prognostic value in CTD-PAH patients. CMR provides additional information on RHC in terms of monitoring the effect of treatment and predicting the prognosis particularly in SSc-PAH patients. SSc-related bi-ventricular interplay may in part explain the poor prognosis of patients with SSc-PAH compared to those with other CTD associated PAH, therefore, SSc associated CTD-PAH and non-SSc associated CTD-PAH could be discriminated as classification category. 
